US Edition
Employers Still Reluctant To Cover Obesity Meds, But Lower Costs May Change This
- Yale researchers analyzed prescription trends for semaglutides and tirzepatides among almost 40 million U.S. adults from 2020 to 2024 using data from 280 health systems.
- They found low prescription rates overall, with disparities by race, ethnicity, gender, and socioeconomic status, as minority and rural populations were less likely to receive these medications.
- These drugs, costing about $1,000 monthly without insurance, are effective for weight loss and reducing cardiovascular risks, but insurance gaps and high out-of-pocket costs limit patient access and fulfillment.
- Yuan Lu highlighted that only a small number of individuals who might gain from these medications are receiving them, noting that certain minority populations experience the highest rates of obesity and have particularly low usage of these treatments.
- Lu concluded that although effective obesity treatments exist, slow adoption and underserved subgroups require targeted efforts to ensure equitable access to these medications.
37 Articles
37 Articles
Tell us: How are you planning to afford GLP-1 drugs? - The Boston Globe
Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your prescription? Planning to pay out of pocket if your coverage ends? We want to hear from you.
Editorial: Shifting the scales requires bold action
News that the government is considering offering free weight-loss drugs for those with a body mass index of over 35 to target the obesity epidemic was widely met with derision.The verbal flagellation was sparked by Health Minister Jo Etienne Abela’s description of semaglutide jabs – such as Ozempic and Wegovy – as a “quick fix”....
The resignation is giving us its last hilts in the first quarter of the 21st century. Especially, the one that invites us to console ourselves with the genetic lottery that has touched us, or to accept the traces of the passage of time that until recently was considered “inexorable” and now, namely...
Scientists Flip the Brain’s “Fat-Off” Switch – Weight Loss Without Side Effects
Scientists have discovered a specific set of brain cells responsible for the weight loss effects of semaglutide, a popular drug for obesity and type 2 diabetes. By isolating these neurons, researchers induced similar results without the drug – appetite reduction and fat loss – and found these benefits were disconnected from the drug’s unpleasant side [...]
For diabetics, weight-loss drugs might lessen cancer risk, study finds
Excess body weight can raise the risk of certain cancers. So researchers have been wondering: Might blockbuster weight-loss drugs like Wegovy, Ozempic and Zepbound also play a role in cancer prevention?Now, a study being presented at a major cancer research conference study in Chicago suggests they could.The study found a slightly lower risk of obesity-related cancers among adults in the United States with diabetes who took these popular medicat…
Coverage Details
Bias Distribution
- 58% of the sources are Center
To view factuality data please Upgrade to Premium
